EP1530973A3 - Verfahren zur Anregung von T-Zelltoleranz zu einem Gewebe- oder Organtransplantat - Google Patents
Verfahren zur Anregung von T-Zelltoleranz zu einem Gewebe- oder Organtransplantat Download PDFInfo
- Publication number
- EP1530973A3 EP1530973A3 EP05075209A EP05075209A EP1530973A3 EP 1530973 A3 EP1530973 A3 EP 1530973A3 EP 05075209 A EP05075209 A EP 05075209A EP 05075209 A EP05075209 A EP 05075209A EP 1530973 A3 EP1530973 A3 EP 1530973A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- tissue
- antagonist
- allogeneic
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 210000000056 organ Anatomy 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 5
- 102100032937 CD40 ligand Human genes 0.000 abstract 4
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 abstract 4
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 abstract 4
- 230000000735 allogeneic effect Effects 0.000 abstract 4
- 239000005557 antagonist Substances 0.000 abstract 4
- 210000001519 tissue Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000284 resting effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/234,987 US5683693A (en) | 1994-04-25 | 1994-04-25 | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
US234987 | 1994-04-25 | ||
EP95917593A EP0757557B1 (de) | 1994-04-25 | 1995-04-25 | Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95917593A Division EP0757557B1 (de) | 1994-04-25 | 1995-04-25 | Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1530973A2 EP1530973A2 (de) | 2005-05-18 |
EP1530973A3 true EP1530973A3 (de) | 2006-12-27 |
Family
ID=22883593
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05075209A Withdrawn EP1530973A3 (de) | 1994-04-25 | 1995-04-25 | Verfahren zur Anregung von T-Zelltoleranz zu einem Gewebe- oder Organtransplantat |
EP95917593A Expired - Lifetime EP0757557B1 (de) | 1994-04-25 | 1995-04-25 | Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95917593A Expired - Lifetime EP0757557B1 (de) | 1994-04-25 | 1995-04-25 | Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat |
Country Status (34)
Country | Link |
---|---|
US (4) | US5683693A (de) |
EP (2) | EP1530973A3 (de) |
JP (1) | JP2974415B2 (de) |
KR (1) | KR100468330B1 (de) |
CN (1) | CN1134266C (de) |
AP (1) | AP764A (de) |
AT (1) | ATE288281T1 (de) |
AU (1) | AU710925B2 (de) |
BG (1) | BG62121B1 (de) |
BR (1) | BR9507509A (de) |
CA (1) | CA2188672A1 (de) |
CZ (1) | CZ291266B6 (de) |
DE (1) | DE69533984T2 (de) |
DK (1) | DK0757557T3 (de) |
EE (1) | EE03516B1 (de) |
ES (1) | ES2237757T3 (de) |
FI (1) | FI118792B (de) |
GE (1) | GEP20022648B (de) |
HU (1) | HU221752B1 (de) |
IS (1) | IS2118B (de) |
LT (1) | LT4309B (de) |
LV (1) | LV11785B (de) |
MD (1) | MD1444B2 (de) |
NO (2) | NO319787B1 (de) |
NZ (1) | NZ284905A (de) |
OA (1) | OA10591A (de) |
PL (1) | PL180031B1 (de) |
PT (1) | PT757557E (de) |
RO (1) | RO114743B1 (de) |
RU (1) | RU2169009C2 (de) |
SI (1) | SI9520057A (de) |
SK (1) | SK136996A3 (de) |
UA (1) | UA44892C2 (de) |
WO (1) | WO1995028957A2 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070777B1 (en) * | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US6472510B1 (en) | 1992-02-14 | 2002-10-29 | Bristol-Myers Squibb Company | CD40 receptor ligands |
ZA946765B (en) * | 1993-09-02 | 1996-02-15 | Dartmouth College | Methods of prolonged suppression of humoral immunity |
EP0721469B1 (de) * | 1993-09-02 | 2000-01-05 | Trustees of Dartmouth College | Anti-gp39 antikoerper und deren verwendungen |
US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
DK0892643T4 (da) * | 1996-03-20 | 2009-12-14 | Bristol Myers Squibb Co | Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved |
IL130785A0 (en) * | 1997-01-10 | 2001-01-28 | Biogen Inc | Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same |
EP1754490A3 (de) * | 1997-06-20 | 2010-01-20 | Biogen Idec MA Inc. | CD154-Blockadetherapie der Pankreasinselzellentransplantation bei Primaten |
CN1195546C (zh) * | 1997-06-20 | 2005-04-06 | 拜奥根有限公司 | 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途 |
US20050031611A1 (en) * | 1998-05-08 | 2005-02-10 | Beth Israel Deaconess Medical Center | Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis |
DK1100515T3 (da) * | 1998-07-30 | 2005-12-12 | Univ Minnesota | Ex vivo-behandling af allogene og xenogene T-celler med pg39-antagonister |
US20020199218A1 (en) * | 1999-08-19 | 2002-12-26 | Daphne Goring | Proline-rich extensin-like receptor kinases |
RU2162297C1 (ru) * | 1999-11-25 | 2001-01-27 | Камакин Владислав Владимирович | Способ индивидуального подбора оптимального питания человека |
WO2001079555A2 (en) | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
CA2408691A1 (en) | 2000-05-12 | 2001-11-22 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
EP1289554A4 (de) * | 2000-06-02 | 2004-05-26 | Univ Minnesota | Immunotherapeutische methode zur vermeidung der abstossung von inselzellen |
CA2410188A1 (en) * | 2000-06-06 | 2001-12-13 | Idec Pharmaceutical Corporation | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
CN1318086C (zh) | 2000-07-03 | 2007-05-30 | 布里斯托尔-迈尔斯斯奎布公司 | 可溶性ctla4分子用于制备治疗风湿性疾病的药物组合物中的用途 |
CA2364983A1 (en) * | 2000-12-13 | 2002-06-13 | John R. Coleman | Nucleic acid molecules and polypeptides for catabolism of abscisic acid |
WO2002078743A1 (en) * | 2001-02-16 | 2002-10-10 | University Of Rochester | Compositions and methods for reducing tranfusion reactions |
US7597895B2 (en) * | 2001-02-20 | 2009-10-06 | The Governing Council Of The University Of Toronto | Signal peptides, nucleic acid molecules and methods for treatment of caries |
US7556807B2 (en) | 2001-02-20 | 2009-07-07 | Kane Biotech, Inc. | Signal peptides, nucleic acid molecules and methods for treatment of caries |
MXPA03010568A (es) | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles. |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
WO2005006949A2 (en) * | 2003-07-07 | 2005-01-27 | Wagner David H | Methods for predicting development of auto-immune diseases and treatment of same |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
EP1795587A1 (de) * | 2005-12-07 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methode zur direkten Kultivierung von dendritischen Zellen ohne Zentrifugationsschritt |
WO2007103134A2 (en) * | 2006-03-02 | 2007-09-13 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
FR2934140B1 (fr) * | 2008-07-25 | 2010-09-03 | Seb Sa | Couvercle d'appareil electromenager de cuisson comportant un sous-ensemble de filtration |
EP2445932B1 (de) | 2009-06-26 | 2018-02-28 | Soricimed Biopharma Inc. | Soriciden-abgeleitete peptide und verfahren zum nachweisen von trpv-6-krebsarten und medikamentenverabreichung |
WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
CN107249318A (zh) | 2014-12-10 | 2017-10-13 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
RU2580640C1 (ru) * | 2014-12-25 | 2016-04-10 | Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации | Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста |
RU2688172C1 (ru) * | 2018-04-05 | 2019-05-20 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ профилактики отторжения трансплантата трупной почки |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993008207A1 (en) * | 1991-10-25 | 1993-04-29 | Immunex Corporation | Novel cytokine |
EP0555880A2 (de) * | 1992-02-14 | 1993-08-18 | Bristol-Myers Squibb Company | CD40CR-Rezeptor und Liganden dafür |
EP0583799A1 (de) * | 1989-05-23 | 1994-02-23 | Otsuka Pharmaceutical Co., Ltd. | Monoklonale Antikörper gegen das auf der Oberfläche der aktivierten endothelialen Zellen antigenischen Sialoglykoprotein |
WO1994004570A1 (en) * | 1992-08-21 | 1994-03-03 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
EP0595659A2 (de) * | 1992-10-30 | 1994-05-04 | Bristol-Myers Squibb Company | Rezeptorliganden von der extrazellularen Matrix, die die Leukozytenfunktion modulieren |
WO1995006666A1 (en) * | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Anti-gp39 antibodies and uses therefor |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
US5597563A (en) * | 1992-09-04 | 1997-01-28 | Beschorner; William E. | Method induction of antigen-specific immune tolerance |
ZA946765B (en) * | 1993-09-02 | 1996-02-15 | Dartmouth College | Methods of prolonged suppression of humoral immunity |
US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
-
1994
- 1994-04-25 US US08/234,987 patent/US5683693A/en not_active Expired - Lifetime
-
1995
- 1995-04-25 EE EE9600162A patent/EE03516B1/xx not_active IP Right Cessation
- 1995-04-25 ES ES95917593T patent/ES2237757T3/es not_active Expired - Lifetime
- 1995-04-25 CZ CZ19963125A patent/CZ291266B6/cs unknown
- 1995-04-25 MD MD97-0009A patent/MD1444B2/ro unknown
- 1995-04-25 AP APAP/P/1996/000906A patent/AP764A/en active
- 1995-04-25 SI SI9520057A patent/SI9520057A/sl unknown
- 1995-04-25 CA CA002188672A patent/CA2188672A1/en not_active Abandoned
- 1995-04-25 GE GEAP19953439A patent/GEP20022648B/en unknown
- 1995-04-25 NZ NZ284905A patent/NZ284905A/en not_active IP Right Cessation
- 1995-04-25 PT PT95917593T patent/PT757557E/pt unknown
- 1995-04-25 KR KR1019960705968A patent/KR100468330B1/ko not_active IP Right Cessation
- 1995-04-25 JP JP7527745A patent/JP2974415B2/ja not_active Expired - Fee Related
- 1995-04-25 SK SK1369-96A patent/SK136996A3/sk unknown
- 1995-04-25 RO RO96-02051A patent/RO114743B1/ro unknown
- 1995-04-25 DK DK95917593T patent/DK0757557T3/da active
- 1995-04-25 WO PCT/US1995/004832 patent/WO1995028957A2/en active IP Right Grant
- 1995-04-25 PL PL95317022A patent/PL180031B1/pl unknown
- 1995-04-25 CN CNB951935623A patent/CN1134266C/zh not_active Expired - Fee Related
- 1995-04-25 EP EP05075209A patent/EP1530973A3/de not_active Withdrawn
- 1995-04-25 DE DE69533984T patent/DE69533984T2/de not_active Expired - Fee Related
- 1995-04-25 EP EP95917593A patent/EP0757557B1/de not_active Expired - Lifetime
- 1995-04-25 BR BR9507509A patent/BR9507509A/pt not_active Application Discontinuation
- 1995-04-25 AT AT95917593T patent/ATE288281T1/de not_active IP Right Cessation
- 1995-04-25 AU AU23585/95A patent/AU710925B2/en not_active Ceased
- 1995-04-25 UA UA96114392A patent/UA44892C2/uk unknown
- 1995-04-25 HU HU9602924A patent/HU221752B1/hu not_active IP Right Cessation
- 1995-04-25 RU RU96122475/14A patent/RU2169009C2/ru not_active IP Right Cessation
-
1996
- 1996-10-18 NO NO19964440A patent/NO319787B1/no unknown
- 1996-10-22 IS IS4378A patent/IS2118B/is unknown
- 1996-10-23 FI FI964272A patent/FI118792B/fi active
- 1996-10-24 OA OA60909A patent/OA10591A/en unknown
- 1996-11-19 BG BG100991A patent/BG62121B1/bg unknown
- 1996-11-25 LT LT96-165A patent/LT4309B/lt not_active IP Right Cessation
- 1996-11-25 LV LVP-96-440A patent/LV11785B/en unknown
-
1997
- 1997-08-05 US US08/906,332 patent/US5902585A/en not_active Expired - Lifetime
-
1999
- 1999-01-05 US US09/227,081 patent/US6375950B1/en not_active Expired - Lifetime
-
2004
- 2004-10-07 US US10/962,033 patent/US7501124B2/en not_active Expired - Fee Related
-
2005
- 2005-03-04 NO NO20051182A patent/NO20051182L/no not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0583799A1 (de) * | 1989-05-23 | 1994-02-23 | Otsuka Pharmaceutical Co., Ltd. | Monoklonale Antikörper gegen das auf der Oberfläche der aktivierten endothelialen Zellen antigenischen Sialoglykoprotein |
WO1993008207A1 (en) * | 1991-10-25 | 1993-04-29 | Immunex Corporation | Novel cytokine |
EP0555880A2 (de) * | 1992-02-14 | 1993-08-18 | Bristol-Myers Squibb Company | CD40CR-Rezeptor und Liganden dafür |
WO1994004570A1 (en) * | 1992-08-21 | 1994-03-03 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
EP0595659A2 (de) * | 1992-10-30 | 1994-05-04 | Bristol-Myers Squibb Company | Rezeptorliganden von der extrazellularen Matrix, die die Leukozytenfunktion modulieren |
WO1995006666A1 (en) * | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Anti-gp39 antibodies and uses therefor |
WO1995006481A1 (en) * | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
Non-Patent Citations (4)
Title |
---|
DURIE, F. ET AL.: "Allogeneic Tolerance induced by Treatment with an Antibody to the Ligand for CD40", FASEB JOURNAL, ABSTRACTS, PART I, vol. 8, no. 4, 15 March 1994 (1994-03-15), pages a477, XP008068753 * |
DURIE, F. ET AL.: "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune disease", RES. IMMUNOL., vol. 145, no. 3, March 1994 (1994-03-01), pages 200 - 205, XP000579835 * |
DURIE, F. ET AL.: "The Role of CD40 in the Regulation of Humoral and Cell-mediated Immunity", IMMUNOL. TODAY, (ELSEVIER SCIENCE LTD), vol. 15, no. 9, pages 406 - 411, XP002398357 * |
FOY, M. ET AL.: "The Expansive Role of CD40 and its Ligand, gp39, in Immunity", SEMIN. IMMUNOL., vol. 6, no. 5, 31 October 1994 (1994-10-31), pages 259 - 266, XP002405170 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1530973A3 (de) | Verfahren zur Anregung von T-Zelltoleranz zu einem Gewebe- oder Organtransplantat | |
RU96122475A (ru) | Способы индуцирования т-клеточной толерантности к тканевому или органному трансплантанту | |
Shevach | The effects of cyclosporin A on the immune system. | |
Skuk et al. | Successful myoblast transplantation in primates depends on appropriate cell delivery and induction of regeneration in the host muscle | |
US8916147B2 (en) | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance | |
CA2387542A1 (en) | Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation | |
JP2002506831A5 (de) | ||
WO1996012794A3 (en) | Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity | |
WO1998020932A3 (en) | Conditioning for allogeneic stem cell transplantation | |
Gurevitch et al. | TRANSPLANTATION OF ALLOGENEIC OR XENOGENEIC BONE MARROW WITHIN THE DONOR STROMAL MICROENVIRONMENT1 | |
CA2284079A1 (en) | Immunotoxins and methods of inducing immune tolerance | |
Prigozhina et al. | PERMANENT AND SPECIFIC TRANSPLANTATION TOLERANCE INDUCED BY A NONMYELOABLATIVE TREATMENT TO A WIDE VARIETY OF ALLOGENEIC TISSUES: I. Induction of Tolerance by a Short Course of Total Lymphoid Irradiation and Selective Elimination of the Donor-Specific Host Lymphocytes: 1 | |
CA2272130A1 (en) | Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3) | |
Lubaroff et al. | The abolition of tolerance of skin homografts in rats with isoantiserum | |
Yamasaki et al. | Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts | |
Kobayashi et al. | Migration of donor cells into the thymus is not essential for induction and maintenance of systemic tolerance after liver transplantation in the rat. | |
Ajiki et al. | Generation of donor hematolymphoid cells after rat-limb composite grafting | |
MX9605051A (es) | Metodos para inducir la tolerancia de celulas t a un injerto u organo. | |
Rao et al. | The two-way paradigm of transplantation immunology | |
DE69527640T2 (de) | Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten | |
CA2218166A1 (en) | Methods of inducing immune tolerance using immunotoxins | |
WO1996032137B1 (en) | Methods of inducing immune tolerance using immunotoxins | |
Achauer et al. | Immunosurgery | |
WO2001000679A3 (en) | Methods for inducing t cell non-responsiveness to a tissue or organ graft | |
Tsuchida et al. | Vascularized bone-marrow allotransplantation in rats prolongs the survival of simultaneously grafted alloskin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050127 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 0757557 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROSSINI, ALDO A. Inventor name: NOELLE, RANDOLPH J. Inventor name: MORDES, JOHN P. Inventor name: PARKER, DAVID C. Inventor name: APPEL, MICHAEL C. Inventor name: PHILLIPS, NANCY E. Inventor name: DURIE, FIONA H. Inventor name: GRENIER, DALE L. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PARKER, DAVID C.,OREGON HEALTH & SCIENCE UNIV. Inventor name: MORDES, JOHN P. Inventor name: NOELLE, RANDOLPH J.,DARTMOUTH MEDICAL SCHOOL Inventor name: DURIE, FIONA H. Inventor name: PHILLIPS, NANCY E. Inventor name: GRENIER, DALE L. Inventor name: ROSSINI, ALDO A. Inventor name: APPEL, MICHAEL C. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DURIE, FIONA H. Inventor name: APPEL, MICHAEL C. Inventor name: MORDES, JOHN P. Inventor name: ROSSINI, ALDO A. Inventor name: PARKER, DAVID C.,OREGON HEALTH & SCIENCE UNIV. Inventor name: GRENIER, DALE L. Inventor name: NOELLE, RANDOLPH J.,DARTMOUTH MEDICAL SCHOOL Inventor name: PHILLIPS, NANCY E. |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
PUAF | Information related to the publication of a search report (a3 document) modified or deleted |
Free format text: ORIGINAL CODE: 0009199SEPU |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
D17D | Deferred search report published (deleted) | ||
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20070703 |
|
AKX | Designation fees paid |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080815 |